Who is sponsoring NCT01703910?

NCT01703910 is sponsored by Centro Nacional de Investigaciones Oncologicas CARLOS III.

What condition does NCT01703910 study?

NCT01703910 studies Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease.

What drugs are being tested in NCT01703910?

Interventions: Arm A chemotherapy, arm B chemotherapy.

What is the status of NCT01703910?

NCT01703910 is currently COMPLETED.

Last reviewed 2015-10-08 · How we verify

Phase II Individualized Therapies Selection Study for Patients With Metastatic Colorectal Carcinoma According to the Genomic Expression Profile in Tumor Samples.

NCT01703910 Phase 2 COMPLETED

The purpose of this study is to assess the feasibility of selecting personalized therapies for colon cancer patients who have failed standard treatments, using a new methodology based on the determination of a profile of chemosensitivity by comprehensive genetic expression analysis from tumor samples.

Details

Lead sponsor	Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase	Phase 2
Status	COMPLETED
Enrolment	29
Start date	2012-11
Completion	2014-12

Conditions

Adenocarcinoma of Colon
Adenocarcinoma of Rectum
Metastatic Disease

Interventions

Arm A chemotherapy
arm B chemotherapy

Primary outcomes

Overall survival — 12 months
To determine the tumor progression-free survival at 3 and 6 months (PFS3 and PFS6) in both groups of patients and identify whether there is a statistically significant difference
gene expression profiles — 12 months
Assess the correlation between the gene expression profiles obtained from the CTC and the gene expression profiles obtained from tumor samples from the same patients.

Countries

Spain